Novel diabetes drugs to face higher hurdles?

被引:3
作者
不详
机构
关键词
D O I
10.1038/nrd2415
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In the wake of the decision to keep Avandia on the market, how might the development of drugs for type 2 diabetes change?
引用
收藏
页码:687 / 689
页数:3
相关论文
共 5 条
[1]  
Jones D, 2007, NAT REV DRUG DISCOV, V6, P590
[2]   Finding new treatments for diabetes - How many, how fast ... How good? [J].
Nathan, David M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (05) :437-440
[3]   Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus [J].
Nissen, SE ;
Wolski, K ;
Topol, EJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (20) :2581-2586
[4]   Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes (vol 356, pg 2457, 2007) [J].
Nissen, Steven E. ;
Wolski, Kathy .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (24) :2457-2471
[5]  
2007, AN INTERN MED 0716